

**Amendments To The Claims**

1-41. (Canceled)

42. (Currently amended) A chimeric anti-human CD23 antibody wherein the light chain variable domain consists of the ~~variable domain~~ polypeptide encoded by nucleotides 58-390 of SEQ ID NO: 1, the heavy chain variable domain consists of the ~~variable domain~~ polypeptide encoded by ~~SEQ ID NO: 2~~ nucleotides 48-423 of SEQ ID NO:3, and the constant region is a human constant region selected from the group consisting of human gamma-1 and human gamma-3 constant regions.

43. (Previously presented) The anti-human CD23 antibody of claim 42 wherein the human constant region is a human gamma-1 constant region.

44. (Previously presented) The anti-human CD23 antibody of claim 42 wherein the human constant region is a human gamma-3 constant region.

45. (Currently amended) A composition containing ~~an~~ the anti-human CD23 antibody according to claim 42 and a pharmaceutically acceptable carrier.

46. (Currently amended) A composition containing ~~an~~ the anti-human CD23 antibody according to claim 43 and a pharmaceutically acceptable carrier.

47. (Currently amended) A composition containing ~~an~~ the anti-human CD23 antibody according to claim 44 and a pharmaceutically acceptable carrier.

48. (Currently amended) A chimeric anti-human CD23 antibody wherein the light chain variable domain consists of the ~~variable domain~~ polypeptide encoded by ~~SEQ ID NO: 3~~ nucleotides 67-387 of SEQ ID NO: 5, the heavy chain variable domain consists of the ~~variable domain~~ polypeptide encoded by nucleotides 58-411 of ~~SEQ ID NO: 4~~ nucleotides 58-411 of SEQ ID NO: 7, and the constant region is a human constant region selected from the group consisting of a human gamma-1 constant region and a human gamma-3 constant region.

49. (Currently amended) A chimeric anti-human CD23 antibody wherein the light chain variable domain consists of the ~~variable domain~~ polypeptide encoded by ~~SEQ ID NO: 3~~ nucleotides 67-387 of SEQ ID NO: 5 and the heavy chain variable domain consists of the ~~variable domain~~ polypeptide encoded by ~~SEQ ID NO: 4~~ nucleotides 58-411 of SEQ ID NO: 7 with the exception that the asparagine codon encoded by nucleotides 289-291 of ~~SEQ ID NO: 4~~ SEQ ID NO: 7 is replaced with a lysine codon.

50. (Currently amended) The anti-human CD23 antibody according to claim 48 ~~which comprises~~ wherein the human constant region is a human gamma-1 constant region.

51. (Currently amended) The anti-human CD23 antibody according to claim 48 ~~which comprises~~ wherein the human constant region is a human gamma-3 constant region.

52. (Currently amended) The anti-human CD23 antibody according to claim 49 ~~which comprises~~ wherein the human constant region is gamma-1 constant region.

53. (Previously presented) The anti-human CD23 antibody according to claim 49 which comprises a human gamma-3 constant region.

54. (Currently amended) A composition comprising ~~an~~ the anti-human CD23 antibody according to claim 48 and a pharmaceutically acceptable carrier.

55. (Currently amended) A composition comprising ~~an~~ the anti-human CD23 antibody according to claim 49 and a pharmaceutically acceptable carrier.

56. (Currently amended) A composition comprising ~~an~~ the anti-human CD23 antibody according to claim 50 and a pharmaceutically acceptable carrier.

57. (Currently amended) A composition comprising ~~an~~ the anti-human CD23 antibody according to claim 51 and a pharmaceutically acceptable carrier.

58. (Currently amended) A composition comprising ~~an~~ the anti-human CD23 antibody according to claim 52 and a pharmaceutically acceptable carrier.

59. (Currently amended) A composition comprising ~~an~~ the anti-human CD23 antibody according to claim 53 and a pharmaceutically acceptable carrier.

60. (Canceled)

61. (Previously presented) The composition of claim 45, which composition is a pharmaceutical composition.

62. (Previously presented) The composition of claim 46, which composition is a pharmaceutical composition.

63. (Previously presented) The composition of claim 47, which composition is a pharmaceutical composition.

64. (Previously presented) The composition of claim 54, which composition is a pharmaceutical composition.

65. (Previously presented) The composition of claim 55, which composition is a pharmaceutical composition.

66. (Previously presented) The composition of claim 56, which composition is a pharmaceutical composition.

67. (Previously presented) The composition of claim 57, which composition is a pharmaceutical composition.

68. (Previously presented) The composition of claim 58, which composition is a pharmaceutical composition.

69. (Previously presented) The composition of claim 59, which composition is a pharmaceutical composition.

70-73. (Canceled)